MedCity News March 25, 2025
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease.
A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering the clinic with a trove of company-generated human data already in hand. These data inform Character’s approach to targets for the dry form of age-related macular degeneration and they also indicate which patients are most likely to respond to treatment. Now the startup has $93...
Today's Sponsors
Today's Sponsor